Clinical Trial Update: Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating weekly nab-paclitaxel (Abraxane) plus weekly cetuximab with IMRT in stage III-IVB head and neck squamous cell carcinoma; the study was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Cetuximab (cetuximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: HEAD & NECK Cancer | Phase 1 | Status: COMPLETED